![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0002.jpg)
allied
academies
Page 10
Journal of Pharmacology and Therapeutic Research
Volume 1 Issue 1
December 07-09, 2017 | Rome, Italy
7
th
World Congress on
Clinical Pharmacy and Pharmacy Practice
Clinical Pharmacy 2017
The drug discovery process: From target
identification to clinical trials and drug
registration: Lessons that we learned. A
case history
A
drug discovery program initiates because there
is a disease or clinical condition without suitable
pharmacological treatment. This unmet clinical need
is the underlying driving motivation for starting a
research project. Nowadays, however, the process
of drug discovery is very complex, time consuming,
and resource intensive, requiring multi-disciplinary
expertise and innovative approaches. Recent estimates
suggest that it takes up to 13.5 years and 1.8 billion US
dollars to bring a new drug to the market. There is a
growing urgency to identify and develop more effective,
efficient, and expedient ways to bring safe and effective
products to the market. The drug discovery and
developmental process relies on utilizing relevant and
robust tools, methods, and models that are predictive
of clinical effects in terms of diagnosis, prevention,
therapy, and prognosis. Moreover, there is a growing
emphasis on translational research, a bidirectional
bench to the bedside approach; and in the so called
“drug-repositioning process” that gives an opportunity
to find new uses of existing drugs or molecules with
a tremendous savings of time and money. The drug
discovery pipeline will be exposed, starting from target
identification to clinical trials and drug registration while
illustrating a case history.
Biography
Valeria Pittalà has completed her MSc in CTF, PhD in Pharmaceutical Sciences
at the University of Catania (Italy), and joined Pharmacia Corporation. There she
has worked as Member of Combinatorial Chemistry Group, contributed to the
discovery of Danusertib, currently under clinical investigation, being Co-Inventor of
Bicyclopyrazoles class. Subsequently, she has returned to the University of Catania
as Medicinal Chemistry Professor. She is highly motivated drug discovery Scientist
and project Leader with proven leadership capability, interpersonal skill, and
independence in achieving given objectives. She has published over 60 patents
and peer-reviewed papers in reputed journals and has been serving as an Editorial
Board Member of repute.
vpittala@unict.itValeria Pittalà
University of Catania, Italy
Valeria Pittalà, J Pharmacol Ther Res 2017